Cevimeline (Saligren) is a medication used to alleviate xerostomia in patients with Sjögren's syndrome. As a cholinergic agonist, it promotes salivary secretion by stimulating the M-type muscarinic receptors of the salivary glands.

What are the Precautions for Cevimeline (Saligren) Administration?

Absolute Contraindications

Patients with severe ischemic heart disease (e.g., myocardial infarction, angina pectoris): The medication may exacerbate coronary artery stenosis and lead to disease progression.

Patients with bronchial asthma and chronic obstructive pulmonary disease: It may induce bronchoconstriction and increased mucus secretion, worsening respiratory symptoms.

Patients with obstruction of the digestive tract or bladder neck: The medication may cause smooth muscle contraction and aggravate obstructive symptoms.

Epileptic patients: It may induce epileptic seizures.

Patients with Parkinsonism or Parkinson's disease: It may exacerbate related symptoms.

Patients with iritis: The medication may cause miosis and worsen inflammation.

Populations Requiring Cautious Use

Patients with comorbid diseases (e.g., interstitial pneumonia, pancreatitis, allergic enteropathy, peptic ulcer, biliary tract disease, urinary calculi, benign prostatic hyperplasia with dysuria, hyperthyroidism, systemic sclerosis): The medication may exacerbate the underlying conditions.

Patients with hepatic or renal impairment: Impaired metabolism and excretion may lead to a sustained elevation of plasma drug concentration and increased risk of adverse reactions.

Geriatric patients: Hepatic and renal function is generally declined; treatment should be initiated at a low dose with close observation.

Pregnant and lactating women: Use only when the therapeutic benefit outweighs the potential risk. Animal studies suggest the medication may affect fetal development and is excreted in breast milk; breastfeeding should be suspended during administration.

Precautions for Drug Interactions

Concomitant use with cholinergic agents (e.g., acetylcholine, neostigmine): May potentiate the cholinergic effects of both drugs and increase the risk of adverse reactions.

Concomitant use with anticholinergic agents (e.g., atropine, certain antipsychotics, tricyclic antidepressants): May antagonize the effects of cevimeline and reduce its efficacy.

Concomitant use with hepatic enzyme inhibitors (e.g., quinidine, itraconazole, erythromycin, cimetidine): May inhibit the metabolism of cevimeline, leading to elevated plasma drug concentration and increased risk of adverse reactions.

Concomitant use with hepatic enzyme inducers (e.g., phenobarbital, rifampicin): May accelerate the metabolism of cevimeline, resulting in decreased plasma drug concentration and reduced efficacy.

Monitoring for Cevimeline (Saligren) Administration

Efficacy Monitoring

Salivary secretion volume: Objective improvement assessed by quantitative testing.

Subjective symptoms: Changes in subjective feelings such as xerostomia, dysphagia, and discomfort during speech.

Objective signs: Physician's assessment of oral mucosal moisture through physical examination.

Safety Monitoring

Interstitial pneumonia: Discontinue the medication and seek medical attention immediately if the patient develops new or worsening cough, dyspnea, or fever; chest imaging examinations should be performed if necessary.

Digestive system: Closely monitor for the occurrence of nausea, abdominal pain, diarrhea, vomiting, etc., which are the most common adverse reactions. For long-term users, monitor serum amylase to alert against pancreatitis.

Cardiovascular system: Monitor heart rate and blood pressure, and watch for symptoms such as palpitations and arrhythmias.

Hepatic function: Regularly test indicators such as ALT, AST, and γ-GTP.

Renal function: Monitor urine routine, BUN, etc.

Patient Education and Self-Monitoring

Take the medication strictly after meals as prescribed to reduce gastrointestinal irritation.

Understand potential adverse reactions, especially common symptoms such as nausea and abdominal pain; seek medical attention promptly if such symptoms persist or worsen.

Record changes in personal symptoms and provide a detailed feedback to the physician during follow-up visits.